HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Kang, Hyo Jin ^a   Yi, Yong Weon ^a,b   Hong, Young Bin ^a,c   Kim, Hee Jeong ^a   Jang, Young Joo ^b   Seong, Yeon Sun ^a,b   Bae, Insoo ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Dankook University   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABCC5 PROTEIN, HUMAN; DNA BINDING PROTEIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; HEME OXYGENASE 1; HMOX1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; NFE2L2 PROTEIN, HUMAN; PARAQUAT; TRANSCRIPTION FACTOR NRF2;

ANTIOXIDANT RESPONSIVE ELEMENT; BREAST NEOPLASMS; CELL LINE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; HUMAN; MCF 7 CELL LINE; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE; UPREGULATION;

ANTIOXIDANT RESPONSE ELEMENTS; BREAST NEOPLASMS; CELL LINE; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEME OXYGENASE-1; HUMANS; MCF-7 CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NF-E2-RELATED FACTOR 2; PARAQUAT; RECEPTOR, ERBB-2; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84930214690     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07201     Document Type: Article

References (39)

1. Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26, 6469-6487 (2007).
2. Dent, S., Oyan, B., Honig, A., Mano, M. & Howell, S. HER2-targeted therapy in breast cancer: a systemic review on neoadjuvant trials. Cancer Treat Rev 39, 622-631 (2013).
3. de Hoon, J. P. et al. Taxane resistance in breast cancer: a closed HER2 circuit? Biochim Biophys Acta 1825, 197-206 (2012).
4. Osborne, C. K. & Schiff, R. Mechanism of endocrine resistance in breast cancer. Annu Rev Med 62, 233-247 (2011).
5. Zhang, W. et al. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin 43, 647-653 (2011).
6. Gilani, R. A. et al. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 135, 681-692 (2012).
7. Knuefermann, C. et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22, 3205-3212 (2003).
8. Mitshishi, Y., Motohashi, H. & Yamamoto, M. The Keap1-Nrf2 system incancers: stress response and anabolic metabolism. Front Oncol 2, 200 (2012).
9. Bryan, H. K., Olayanju, A., Goldring, C. E. & Park, B. K. The Nrf2 cell defense pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 85, 705-717 (2013).
10. Ma, Q. Role of Nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53, 401-426 (2013).
11. Niture, S. K., Khatri, R. & Jaiswal, A. K. Regulation of Nrf2-an update. Free Radic Biol Med 66, 36-44 (2014).
12. Nguyen, T., Sherratt, P. J. & Pickett, C. B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43, 233-260 (2003).
13. Rada, P. et al. SCF/β-TrCP promotes glycogen synthase kinase-dependent degradationof the Nrf2 transcription factorinaKeap1-independent manner. Mol Cell Biol 31, 1121-1133 (2011).
14. Rada, P. et al. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis. Mol Cell Biol 32, 3486-3499 (2012).
15. Chowdhry, S. et al. Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32, 3765-3781 (2013).
16. Kang, H. J., Hong, Y. B., Kim, H. J. & Bae, I. CR6-interacting factor 1 (CRIF1) regulates NF-E2-related factor 2 (NRF2) protein stability by proteasomemediated degradation. J Biol Chem 285, 21258-21268 (2010).
17. Chen, W. et al. Direct interaction between Nrf2 and p21Cip1/WAF1 upregulates the Nrf2-mediated antioxidant response. Mol Cell 34, 663-673 (2009).
18. Camp, N. D. et al. Wilms tumor gene on the X chromosome (WTX) inhibits the degradation of NRF2 through competitive binding to KEAP1. J Biol Chem 287, 6539-6550 (2012).
19. Komatsu, M. et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12, 213-223 (2010).
20. Ma, J. et al. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol 32, 1506-1517 (2012).
21. Hast, B. E. et al. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitiniation. Cancer Res 73, 2199-2210 (2013).
22. Gorrini, C. et al. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 210, 1529-1544 (2013).
23. Singh, A. et al. RNAi-mediated silencing of nuclear factor erythroid-3-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res 68, 7975-7984 (2008).
24. Homma, S. et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15, 3423-3432 (2009).
25. Hong, Y. B. et al. Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas 39, 463-472 (2010).
26. Lister, A. et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer 10, 37 (2011).
27. Yamadori, T. et al. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 31, 4768-4777 (2012).
28. Duong, H.-Q. et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol 44, 959-969 (2014).
29. Kang, K. A. et al. Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation. Cell Death Dis 5, e1183 (2014).
30. Li, Y. M. et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6, 459-469 (2004).
31. Bae, I. et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 64, 7893-7909 (2004).
32. Li, J. et al. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 83, 313-328 (2005).
33. Manandhar, S. et al. NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity. Free Radic Biol Med 52, 1773-1785 (2012).
34. Baens, M. et al. The dark side of EGFP: defective polyubiquitination. PLoS One 1, e54 (2006).
35. NEU tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 203, 1589-1598 (1994).
36. Wang, S. C. et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6, 251-261 (2004).
37. Hsu, S. C. & Hung, M. C. Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem 282, 10432-10440 (2007).
38. Béguelin, W. et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol 30, 5456-5472 (2010).
39. Li, L. Y. et al. Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes. Cancer Res 71, 4269-4279 (2011).